Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

140.10USD
4:00pm EDT
Price Change (% chg)

$3.29 (+2.40%)
Prev Close
$136.81
Open
$138.19
Day's High
$141.25
Day's Low
$137.41
Volume
232,027
Avg. Vol
263,414
52-wk High
$176.58
52-wk Low
$74.00

JAZZ.OQ

Chart for JAZZ.OQ

About

Jazz Pharmaceuticals plc, formerly Azur Pharma Public Limited Company, is a specialty biopharmaceutical company. The Company’s marketed products include Xyrem (sodium oxybate oral solution), which is the product approved by the United States Food and Drug Administration (FDA), for the treatment of both cataplexy and excessive... (more)

Overall

Beta: 0.80
Market Cap (Mil.): $8,133.47
Shares Outstanding (Mil.): 59.45
Dividend: --
Yield (%): --

Financials

  JAZZ.OQ Industry Sector
P/E (TTM): 111.74 35.65 36.07
EPS (TTM): 1.22 -- --
ROI: 3.37 18.91 18.18
ROE: 6.66 19.67 19.05
Search Stocks

BUZZ-Jazz Pharmaceuticals Plc: Acquires rights to liver drug

** Acquires U.S. marketing rights for liver drug defibrotide in the U.S. from privately held Sigma Tau Pharmaceuticals Inc for $75 million

02 Jul 2014

Exclusive: Allergan eyes new takeover bid for Shire - sources

LONDON/NEW YORK - Allergan Inc , facing an unsolicited bid from Valeant Pharmaceuticals International Inc , is preparing to approach Shire Plc about a potential takeover, even though the Irish drugmaker rebuffed a previous overture, people familiar with the matter said on Monday.

28 Apr 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks